TYRA241115C17500
- 0.90
- 0.000.00%
TYRA BIOSCIENCES, INC. Newsroom
Chief Financial Officer of Tyra Biosciences Alan Fuhrman Buys 284% More Shares
H.C. Wainwright Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $32
Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday
Tyra Bioscience Cleared by FDA to Conduct Phase 2 Study in Pediatric Achondroplasia
Express News | Tyra Biosciences Inc - First Child With Achondroplasia Expected to Be Dosed in Q1 2025
Express News | Tyra Biosciences Receives Ind Clearance From FDA to Proceed With Phase 2 Study of Tyra-300 in Pediatric Achondroplasia (Beach301)
H.C. Wainwright Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $32
Express News | Tyra Biosciences Inc : H.c. Wainwright Raises Target Price to $32 From $30
12 Health Care Stocks Moving In Friday's Intraday Session
Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday?
Tyra Biosciences Price Target Maintained With a $28.00/Share by Wedbush
Tyra Biosciences Analyst Ratings
Tyra Stock Plunges 17% Amid TYRA-300 Study Data Release
TD Cowen Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating
Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $33
Express News | Tyra Biosciences Inc - Positive Safety Results Across All Qd Doses
Express News | Tyra Biosciences Inc - 4 Serious Adverse Events Related to Tyra-300
Express News | Tyra Biosciences Inc - Tyra-300 Generally Well-Tolerated With Infrequent Fgfr2/Fgfr1 Toxicities
Express News | Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for Tyra-300, an Investigational Oral Fgfr3-Selective Inhibitor, in Phase 1/2 Surf301 Study in Patients With Metastatic Urothelial Cancer (Muc)
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 From SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET